ストックスクリーナーアプリを入手
4.24
2.53%
-0.11
アフターアワーズ：
4.24
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
XFOR SEC FilingsX4 Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Stonepine Capital (QNRX) files Form 4 as 10% owner with no trades - Stock Titan
Is ANIP Undervalued? How to Read Its 9.3x Forward P/E - TradingView
Tech Rally: What analysts say about X4 Pharmaceuticals Inc stock2026 Buyback Activity & Safe Capital Investment Plans - baoquankhu1.vn
Is X4 Pharmaceuticals Inc impacted by rising ratesWeekly Earnings Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Performance Recap: How does X4 Pharmaceuticals Inc score in quality rankings2026 PreEarnings & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Venrock funds trim KalVista (KALV) stake, retain 5.09M shares - Stock Titan
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Global X Japan Co. Ltd. - MarketBeat
Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - BioSpace
Earnings Risk: How correlated is X4 Pharmaceuticals Inc to the S P5002026 Investor Takeaways & Fast Gain Swing Alerts - baoquankhu1.vn
XFOR|X4 Pharmaceuticals Inc|Price:4.090|Chg%:0.27 - TradingKey
[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) - Business Wire
Tarsus Pharmaceuticals (TARS) COO sells 2,989 shares in planned trade - Stock Titan
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong - WHEC.com
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review - Business Wire
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
If You Invested $1,000 in X4 Pharmaceuticals Inc (XFOR) - Stock Titan
X4 Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | | US98420X2027 - marketscreener.com
X4 Pharmaceuticals (NASDAQ:XFOR) Raised to Hold at Wall Street Zen - MarketBeat
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) - PR Newswire
X4 Pharmaceuticals (NASDAQ: XFOR) seeks approval for equity plan and pay at 2026 meeting - Stock Titan
Q3 Earnings Forecast for XFOR Issued By Brookline Cap M - MarketBeat
Tarsus (NASDAQ: TARS) HR chief sells 12,274 shares in tax-related trades - Stock Titan
Tax-driven stock sale by Tarsus (TARS) chief commercial officer - Stock Titan
Children’s ibuprofen sold nationwide recalled by FDA - FOX8 WGHP
Analysts’ Top Healthcare Picks: X4 Pharmaceuticals (XFOR), Boston Scientific (BSX) - The Globe and Mail
Research Analysts Set Expectations for XFOR Q1 Earnings - MarketBeat
Crinetics Pharmaceuticals (CRNX) COO sells 9,911 shares for RSU taxes - Stock Titan
Crinetics (NASDAQ: CRNX) CSO sells shares to cover RSU tax - Stock Titan
RA Capital entities boost Acumen (NASDAQ: ABOS) stake with 6.1M-share grant - Stock Titan
X4 Pharmaceuticals (NASDAQ:XFOR) Issues Quarterly Earnings Results - MarketBeat
Amphastar (AMPH) EVP Yakob has 1,033 shares withheld for RSU tax - Stock Titan
[Form 4] Amphastar Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
X4 Pharmaceuticals, Inc. 2025 Annual Report: Business Overview, Regulatory Compliance, and Risk Factors - Minichart
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
XFOR: 4WARD Phase 3 trial progresses, EMA backs mavorixafor, and cash runway extends to 2028 - TradingView
X4 Pharmaceuticals: Q4 Earnings Snapshot - 10tv.com
EMA panel backs first WHIM syndrome drug as X4 secures cash to 2028 - Stock Titan
X4 Pharmaceuticals 2025 10-K: $35.1M Revenue, $(79.2)M Net Loss - TradingView
XFOR: 2025 revenue surged to $35.1M, but net loss increased to $79.2M amid restructuring and R&D focus - TradingView
X4 Pharmaceuticals (NASDAQ: XFOR) cuts costs, raises cash to advance mavorixafor - Stock Titan
X4 Pharmaceuticals (XFOR) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
X4 Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy (AMRX) - Seeking Alpha
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - TradingView
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Jain Global LLC - MarketBeat
X4 Pharmaceuticals, Inc. $XFOR Shares Acquired by Kingdon Capital Management L.L.C. - MarketBeat
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by HighVista Strategies LLC - MarketBeat
Aug Sectors: Is X4 Pharmaceuticals Inc impacted by rising ratesPortfolio Risk Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
X4 Pharmaceuticals Inc (XFOR) Stock News & Articles - 24/7 Wall St.
Apellis (NASDAQ: APLS) CEO gifts 129,738 shares via family trusts - Stock Titan
Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now? - TradingView
Rosalind Advisors Inc. Makes New Investment in X4 Pharmaceuticals, Inc. $XFOR - MarketBeat
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Equity awards and tax withholding for Amphastar Pharmaceuticals (AMPH) insiders - Stock Titan
Recursion (NASDAQ: RXRX) director converts 20K Class B, gifts 20K A - Stock Titan
X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology - Investing.com
Amphastar (AMPH) CEO logs 10,850-share RSU tax withholding, retains large stake - Stock Titan
Geopolitical Volatility Boosts Value Investing: 4 Low-PEG Picks - TradingView
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Summary: Is X4 Pharmaceuticals Inc impacted by rising ratesTrade Analysis Report & Stepwise Swing Trade Plans - baoquankhu1.vn
Amylyx (NASDAQ: AMLX) CFO receives new stock options and RSU grant - Stock Titan
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - Yahoo Finance
Guggenheim initiates X4 Pharmaceuticals stock with buy rating - Investing.com Australia
0.49%
1.47%
大文字化:
|
ボリューム (24 時間):